title: Incidence and clinical epidemiology of streptococcal septicemia during treatment of acute myeloid leukemia.
abstract: The incidence and outcome of streptococcal septicemia was analyzed in 76 consecutive patients with newly diagnosed and relapsed acute myeloid leukemia. They received 215 courses of remission induction or intensive consolidation treatment. There were 31 different episodes of streptococcal septicemia in 27 patients, making these microorganisms the most frequently encountered bacteria in blood cultures. This high incidence coincided with the introduction of selective intestinal decontamination. In 24 episodes (20 patients) there was a fast recovery, but 7 patients developed pulmonary symptoms resulting in death due to respiratory failure in 5 of them. The infections all occurred in the phase of maximum bone marrow suppression 1-3 weeks after the start of the chemotherapy. Streptococcal septicemia was not limited to patients treated with cytosine arabinoside but also occurred in patients treated with other regimens of intensive chemotherapy. In 28 episodes there were no focal signs of infection, but in half there were symptoms of treatment induced gastrointestinal toxicity. The streptococci probably invade through oral and gastrointestinal mucosa damaged by the chemotherapy. Selective decontamination may play a promoting role.
authors.affiliation: Department of Hematology, University of Amsterdam, The Netherlands.
authors.forename: H
authors.initials: H
authors.lastname: van der Lelie
authors.forename: R J
authors.initials: RJ
authors.lastname: van Ketel
authors.forename: A E
authors.initials: AE
authors.lastname: von dem Borne
authors.forename: R H
authors.initials: RH
authors.lastname: van Oers
authors.forename: B L
authors.initials: BL
authors.lastname: Thomas
authors.forename: R
authors.initials: R
authors.lastname: Goudsmit
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D006801:Humans; D015994:Incidence; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D011379:Prognosis; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D018805:Sepsis / Q000150:complications / Q000453:epidemiology*; D013290:Streptococcal Infections / Q000150:complications / Q000453:epidemiology*
chemical_list: D003561:Cytarabine; D003520:Cyclophosphamide